Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 31.9% in December

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large decline in short interest in December. As of December 15th, there was short interest totalling 119,400 shares, a decline of 31.9% from the November 30th total of 175,300 shares. Approximately 0.6% of the company’s stock are sold short. Based on an average daily volume of 424,600 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, Raymond James reduced their price target on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

Xilio Therapeutics Trading Down 0.3 %

Shares of XLO stock opened at $0.97 on Friday. The stock’s 50-day moving average price is $1.04 and its 200-day moving average price is $0.93. Xilio Therapeutics has a 12-month low of $0.50 and a 12-month high of $1.93. The stock has a market capitalization of $42.74 million, a price-to-earnings ratio of -0.57 and a beta of -0.29.

Institutional Investors Weigh In On Xilio Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its position in Xilio Therapeutics by 85.0% during the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after acquiring an additional 155,337 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Xilio Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock worth $280,000 after buying an additional 45,554 shares during the period. Finally, XTX Topco Ltd acquired a new position in Xilio Therapeutics during the second quarter valued at $32,000. 54.29% of the stock is owned by institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.